Our aim was to compare the efficacy and safety of bivalirudin (Biv) versus heparin (Hep) with or without similar usage rate of glycoprotein IIb/IIIa inhibitors (GPIs) during percutaneous coronary intervention (PCI). The PubMed and EMbase were searched. Randomized trials comparing Biv versus Hep were eligible for inclusion. With imbalanced GPI use, Biv had significantly lower major bleeding (pooled risk ratio [RR], 0.67; 95% confidence interval [CI], 0.54-0.83) without difference in mortality (pooled RR, 0.95; 95% CI, 0.80-1.14). With comparable GPI use, no significant difference was observed in major bleeding (pooled RR, 0.95; 95% CI, 0.82-1.10) and mortality (pooled RR, 1.13; 95% CI, 0.85-1.50). With no GPI use, Biv was associated with numerically higher mortality (pooled RR, 1.17; 95% CI, 0.83-1.65) without significant difference in major bleeding (pooled RR, 0.81; 95% CI, 0.64-1.02). In conclusion, when comparing different anticoagulants during PCI, the effect of GPIs should not be underestimated. Heparin as such was found noninferior to Biv.
JneidHAndersonJLWrightRS. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60(7):645–681.
2.
StegPGvan ‘t HofAHammCW. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013;369(23):2207–2217.
3.
KastratiANeumannFJSchulzS. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med. 2011;365(21):1980–1989.
4.
StoneGWWhiteHDOhmanEM. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007;369(9565):907–919.
5.
GibsonCMMorrowDAMurphySA. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006;47(12):2364–2373.
6.
LincoffAMBittlJAHarringtonRA. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289(7):853–863.
7.
SciahbasiARigattieriSCorteseB. Bivalirudin or heparin in primary angioplasty performed through the transradial approach: results from a multicentre registry. Eur Heart J Acute Cardiovasc Care. 2014;3(3):268–274.
8.
MacHaalanyJAbdelaalEBatailleY. Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention. Am J Cardiol. 2012;110(12):1742–1748.
9.
HibbertBMacDougallALabinazM. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry. Circ Cardiovasc Interv. 2012;5(6):805–812.
10.
ShahNNatarajanDKRafiudeenR. PT208 bivalirudin versus heparin alone in primary PCI for ST-segment elevation myocardial infarction. Global Heart. 2014;9(1):e208.
11.
HigginsJPTGreenS.Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. The Cochrane Collaboration; Copenhagen, DK, 2011. www.cochrane-handbook.org. Accessed on January 19, 2015.
12.
XiangDCGuXLSongYM. Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention. Chin Med J (Engl). 2013;126(16):3064–3068.
13.
WaksmanRBertrandODriesmanM. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III). J Interv Cardiol. 2013;26(2):107–113.
14.
DeshpandeNVPratitiRAdmanePMukherjeeDMardikarHM. Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention. Indian Heart J. 2012;64(5):444–448.
15.
PattiGPasceriVD’AntonioL. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study). Am J Cardiol. 2012;110(4):478–484.
16.
MoliternoDJ. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Catheter Cardiovasc Interv. 2011;77(7):1001–1009.
17.
KastratiANeumannFJMehilliJ. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359(7):688–696.
18.
LincoffAMBittlJAKleimanNS. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol. 2004;93(9):1092–1096.
19.
LincoffAMKleimanNSKottke-MarchantK. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002;143(5):847–853.
20.
SchulzSRichardtGLaugwitzKL. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2014;35(34):2285–2294.
21.
StoneGWWitzenbichlerBGuagliumiG. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218–2230.
22.
ParodiGMiglioriniAValentiR. Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial). Am J Cardiol. 2010;105(8):1053–1059.
23.
ShahzadAKempIMarsC. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014;384(9957):1849–1858.
24.
FeldmanASuleimanKBushariLRoznerEFreedbergNATurgemanY. bivalirudin vs unfractionated heparin during percutaneous coronary intervention in high risk patients for bleeding. AntiCoagulant Regimen In high risk PAtients for Bleeding—ACRIPAB Trial. Eur Heart J. 2012;33:842–842
25.
TavanoDViscontiGD’AndreaD. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention. Am J Cardiol. 2009;104(9):1222–1228.
TarantiniGBrenerSJBarioliA. Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials. Am Heart J. 2014;167(3):401–412.
28.
BonelloLde LabriolleARoyP. Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty. Cardiovasc Revasc Med. 2009;10(3):156–161.
29.
BonelloLDe LabriolleARoyP. Bivalirudin with provisional glycoprotein IIb/IIIa inhibitors in patients undergoing primary angioplasty in the setting of cardiogenic shock. Am J Cardiol. 2008;102(3):287–291.
30.
LupiARognoniACavallinoC. Pharmacological adjuvant therapies in primary coronary interventions: bivalirudin. Cardiovasc Hematol Agents Med Chem. 2013;11(2):106–114.
31.
InvestigatorsE. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336(24):1689–1696.
32.
InvestigatorsTE. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356(9247):2037–2044.
33.
SchomigASchmittCDibraA. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J. 2005;26(14):1379–1384.
34.
MehilliJKastratiASchulzS. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009;119(14):1933–1940.
35.
Di MarioC. Rise and fall of glycoprotein IIb-IIIa inhibitors in ST-segment elevation myocardial infarction. Heart. 2014;100(11):823–824.
36.
HamonMRasmussenLHManoukianSV. Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial. EuroIntervention. 2009;5(1):115–120.
37.
BittlJAStronyJBrinkerJA. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med. 1995;333(12):764–769.
38.
ShahPBAhmedWHGanzPBittlJA. Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions. J Am Coll Cardiol. 1997;30(5):1264–1269.
39.
LefkovitsJTopolEJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation. 1994;90(3):1522–1536.
40.
HelftGBeyguiFle FeuvreCMetzgerJP. Defining the optimal activated clotting times during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001;104(22):E124.
41.
FeldmanDNMinutelloRMBergmanGMoussaIWongSC. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. Catheter Cardiovasc Interv. 2010;76(4):513–524.
